Angiotensin II receptor antagonists and hypertension.
Over recent years, a number of imidazole derivatives that specifically bind to the angiotensin II type 1 receptor, thereafter called sartans, have been developed and made available to the clinician. Whether targeting antihypertensive treatment with such a high specificity within the renin cascade may carry major clinical advantage over inhibiting angiotensin converting-enzyme remains to be demonstrated. In short-term studies, the efficacy of these drugs at reducing blood pressure was similar to that of established comparators, whereas overall side effect profile was comparable to that of placebo.
Mimran
A
A
Department of Medicine, Centre Hospitalier Universitaire, Montpellier, France.
Ribstein
J
J
DuCailar
G
G
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000493:pharmacokinetics / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy*; D007674:Kidney Diseases / Q000188:drug therapy; D019808:Losartan / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D014652:Vascular Diseases / Q000188:drug therapy
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D000804:Angiotensin II; D019808:Losartan